HomeLatestBig Pharma Makes Big Investment in Psychedelic Drug Company
Big Pharma Makes Big Investment in Psychedelic Drug Company
January 06, 2022 at 11:35 am - by Kerry Corbit
Psychedelic drugs have come a long way since the ‘60s. Once hailed for social and recreational purposes, today LSD, magic mushrooms and other psychedelics are headlining clinical trials for novel treatments for depression and anxiety, addiction, PTSD and schizophrenia, among others.
Big pharma is paying attention. Recently, the McQuade Center for Strategic Research and Development (the U.S. segment of the well-known Japanese drug maker, Otsuka Pharmaceutical Co.) announced its plans to fund $5 million for the development of two new “mindset drug” compounds. While psychedelic drugs are still largely illegal, clinical trials and positive results are beginning to shift their reputation.
In addition to Otsuka, which offers therapeutics for mental health issues and central nervous disorders, other companies and big names are focusing on the broader uses of mindset drugs and the need for decriminalization. Johns Hopkins Medicine, for instance, garnered the first federal grant to study magic mushrooms, formally known as psilocybin, and Peter Thiel, co-founder of PayPal Holdings, has invested deeply in psychedelic start-up Atai Life Sciences (Nasdaq: ATAI). Meanwhile, Oregon became the first state to legalize mindset drugs for therapeutic use while Washington, D.C. voters recently supported the decriminalization of psychedelics used medicinally.
With the global psychedelic drug market expected to grow to over $69 billion by 2026, investors are recognizing their potential, likening psychedelics to marijuana, which has gained broader social and commercial acceptance in recent years. As big pharma continues to stake its claim in psychedelics, more trials and industry growth are anticipated.
If you are looking for some small cap companies in the psychedelic space, consider the following stocks:
CYBN(Cybin) – Cybin Inc., is a biotechnology company, which focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions.
MNMD (Mind Medicine) – Mind Medicine (MindMed) Inc., is a psychedelic medicine biotech company, which discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.
CMPS(COMPASS Pathways) – COMPASS Pathways plc operates as a mental health care company, which develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression.
FTRP(Field Trip Health) – Field Trip Health Ltd. engages in the development and delivery of psychedelic therapies and the company operates Field Trip Health Centers that provide psychedelic therapies; offers Field Trip Digital apps; and Field Trip Discovery, a drug development division developing the next generation of psychedelic molecules.
“PCG” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PCG” engage in any activities that would require such registrations. “PCG” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PCG” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PCG”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PCG” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.